Delavirdine (Rescriptor) approved.
James
J S
JS
D019380:Anti-HIV Agents / Q000627:therapeutic use; D020008:Delavirdine; D016049:Didanosine / Q000627:therapeutic use; D017277:Drug Approval; D016527:Drug Costs; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D020008:Delavirdine; D016049:Didanosine